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hat is the connection between McAllen, 
Texas and our Lipoproteins and Vascu-
lar Diseases Division? That is a relevant 
story for this issue of FATS. 
 
McAllen is a Texas border town with the lowest 
per capita income in the US, but one of the highest 
per capita Medicare costs. Their income averages 
$12,000, compared to average Medicare costs of 
$15,000, which means that each eligible person 
consumes more than their total income in health 
care costs. And of course the Federal Government 
or rather we as taxpayers make up the difference! 
This unfortunate story is detailed in a highly inter-
esting article by Atul Gawande in The New Yorker 
issue of June 1, 2009. The author, in the typical 
thoughtful and lucid New Yorker style, contrasts 
McAllen with other communities with much lower 
health care costs, even as low as one third of those 
in McAllen such as Rochester MN, home of the 
Mayo Clinic, Marshfield WI with their well known 
clinic, and Boise ID. And, by various indices, over-
all quality of care is actually better in the lower cost 
communities; evidence suggests there is little re-
lationship between quality of health care and cost. 
 
According to the author, the primary difference 
affecting medical costs is neither the quality of care 
nor the burden added by excessive and defensive 
medicine to avoid malpractice claims, but rather in 
the intent of the medical providers. In McAllen, 
the primary focus has evolved to be more on the 
business aspects, using medical services to drive 
revenue with the care entities viewed as profit cen-
ters. By contrast, in the lower cost areas, the focus 
tends to be more on the service aspects of medical 
care. Providers in areas with lower costs tend to 
take a more integrated and preventive approach, 
including focusing on the overall needs of the pa-
tient rather than simply treating and billing. 
 
We are all aware that delivery of healthcare and the 
associated economics are again much in the news 
                                                
http://www.newyorker.com/reporting/2009/06/
01/090601fa_fact_gawande 
and a stated priority of the current US administra-
tion. And it is about time. Per capita healthcare 
costs in the US are more than double those of the 
next highest county, Switzerland, and currently 
consume about 17% of the GDP. At the current 
rate of increase and in the absence of major 
intervention, runaway costs will bankrupt the 
country in our lifetimes. And this problem is not 
limited to the US. Increasing medical costs follow 
chronic conditions such as the cardiovascular dis-
eases and their precursors; smoking, obesity, meta-
bolic syndrome and diabetes, which are spreading 
with the western lifestyle throughout the world. 
The World Health Organization predicts by next 
year cardiovascular diseases will become the major 
cause of morbidity and mortality worldwide. 
 
Among many other changes, fixing health care 
must shift attention from the current focus on 
treatment, with often expensive interventions, to 
prevention of diseases. A more prevention-
oriented system will help in controlling exploding 
medical costs. And, speaking of prevention, this 
brings us to the Lipoproteins and Vascular Dis-
eases Division, which this year celebrates 20 years 
as a permanent division following the first 3 years 
as a provisional division of AACC. “Old timers” 
will remember the division had its genesis in the 
aftermath of the Lipid Research Clinics program. 
The LRC Coronary Primary Prevention Trial, 
funded by NIH through the Lipid Research Clin-
ic’s Program, reported in 1984, was the first major 
placebo controlled study to demonstrate that low-
ering cholesterol could reduce CVD events. This 
study lead to the NIH sponsored National Choles-
terol Education Program and the consensus based 
Adult Treatment Panel guidelines for managing 
patients at risk, first released in 1988. Mevacor, or 
lovastatin, the first commercially successful statin 
drug, came into use in the US in 1987 and lead to 
the succession of increasingly effective statins, 
which have contributed to declining CVD event 
rates. These developments provided the evidence 
and the tools to enable a shift from treating the 
consequences of CVD to preventing the develop-
ment of the underlying atherosclerosis. However, 
this changing focus has already consumed two 
W
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decades and must progress even further to reduce 
the burden of cardiovascular diseases in the US 
and other countries throughout the world. 
 
That exciting period in the mid to late 1980s was a 
major turning point in the move towards preven-
tion. And the LVDD has been a major contributor 
from the beginning. LVDD members have lead 
efforts to improve and standardize the lipid/lipo-
protein assays, making test results more uniform 
and reliable. Members have contributed many im-
portant technical papers to the literature and 
organized various presentations to lab and physic-
cian groups. The Division has also sponsored edu-
cational programs such as the early Manufacturer’s 
Workshops and the current International Stan-
dardization Programs. Informative books have 
been published through individual and collective 
efforts such as the Handbook of Lipoprotein Testing. 
 
Now, hopefully, we are at another turning point in 
the practice of medicine. We in the LVDD can 
proudly claim that we have been on the right side 
of history already for over two decades as our 
focus from the beginning has been driving and 
supporting preventive efforts. As we move for-
ward into this new era in medical practice our sup-
port will continue to be crucial. We will of course 
still provide reliable lab values, which are the basis 
for characterizing, treating and monitoring pa-
tients. We will continue to develop more definitive 
and cost effective assays for better identifying 
patients at risk. And we will need to continue 
educating practitioners in the nuances of emerging 
technologies. 
 
Those still active in the Division 20 years hence 
may look back with even greater satisfaction, hav-
ing assisted in conquering cardiovascular diseases 
and thereby contributing to a relative decline in 
health care costs. That is provided we all as pro-
fessionals and as citizens make the appropriate de-
cisions now. And McAllen, TX may look forward 
to a day when their residents spend only a fraction 
of their total income on health care. 
 
Russ Warnick, Editor 
The Fats of Life 
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he Summer issue of the FOL is always 
associated with the Annual AACC meeting, 
which will take place in Chicago this year. 
In addition to the usual executive meeting on Sun-
day, LVDD again has two major evening events. 
On Monday night, the traditional award ceremony 
and celebration of the 20th anniversary of LVDD 
will be followed by two high-quality presentations. 
On Tuesday night, two other high-quality presen-
tations will discuss current issues in cardiovascular 
research and testing. A detailed description of 
these events has already appeared in the Chair’s 
Corner section of the Spring issue of the FOL and 
is retrievable from AACC-LVDD’s website, so the 
following is just a brief summary for time and 
location: 
 
LVDD EXECUTIVE COMMITTEE (BOARD) 
MEETING 
(Since this also serves as a division business meet-
ing, no registration is required and all members are 
invited and welcome!) 
 Sunday, July 19  8:00am – 11:00am 
 Hyatt Regency Chicago Hotel (Columbian Rm) 
 
ANNUAL LVDD DINNER MEETING 
Current Topics in Cardiovascular Disease 
 Monday, July 20 - 5:30pm – 9:30pm 
 Hyatt Regency Chicago Hotel (Columbus Hall 
A, B, C, D) 
International Lipoprotein Standardization Forum 
 Tuesday, July 21 - 6:00pm – 9:30pm 
 Hyatt Regency Chicago Hotel (Columbus Hall 
K, L) 
 
Although it may be difficult, if not impossible, to 
define the precise time for the foundation of our 
division (it took a few years from the original 
thought to formalize the division at AACC), we 
decided to celebrate our 20th anniversary this year. 
Our first Chair (G. Russell Warnick) was elected in 
1989 and this justifies the anniversary in 2009. 
Regretfully, one of our founding members is no 
longer able to participate in this celebration. The 
sad news is Gerald R. Cooper, MD, PhD, often 
referred to as the “Father of Cholesterol,” has 
passed away on May 25, 2009. Dr. Cooper 
published in the first volume of Clinical Chemistry in 
1955 and was one of the Past Presidents of AACC. 
Working at CDC in Atlanta, GA, he spent over 50 
years improving the accuracy and precision of 
serum lipid testing. He was a major force behind 
the Cholesterol Standardization Program and he 
continued to have a productive life by actively 
working in this area almost until his death at the 
age of 94 years (see his recent publication list, 
below)—his last publication appeared just three 
months before his death this year. LVDD honored 
Dr. Cooper’s extensive contributions to the im-
proved diagnosis of cardiovascular diseases by 
establishing the Cooper Award in 1992. This 
award is given every other year for outstanding 
contributions to service in the area of lipoproteins 
and vascular diseases and Dr. Cooper was the first 
recipient of it. 
 
Dr. Cooper’s life, career, work ethic, and resolute 
optimism have been described in detail in an 
“Inspiring Minds” article by Misia Landau in the 
2008 September issue of Clinical Chemistry (Landau 
M. “Gerald Cooper.” Clin Chem. 2008 Sep;54(9): 
1578-9). As shown below, this issue also carried a 
sketch of Dr. 
Cooper on its 
cover. Obituaries 
have already ap-
peared about Dr. 
Cooper in the 
AACC eNewsletter 
and the July issue 
of Clinical Labora-
tory News (CLN), 
and an obituary is 
planned for pub-
lication in Clinical 
Chemistry, as well. 
A photograph 
taken just about a 
year ago during 
the 2009 Annual AACC meeting in Washington, 
DC shows the Dr. Cooper full of life and energy, 
as we knew him (see below). In this photo, he is 
accompanied by his colleague and friend, Gary 
T
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Myers, PhD, from CDC, who himself is another 
Past President of AACC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced by permission 
Clin. Lab. News 2009,35(7):18 
Photo: Oscar Enzig Photography 
 
Dr. Cooper’s publications from the last decade 
include the following: 
 
1. NACB LMPG Committee Members, Myers GL, Christen-
son RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer 
CM, Grundy SM, Labarthe DR, Levy D, Rifai N, Wilson 
PW. National Academy of Clinical Biochemistry Laboratory 
Medicine Practice guidelines: emerging biomarkers for pri-
mary prevention of cardiovascular disease. Clin Chem. 2009 
Feb;55(2):378-84. Epub 2008 Dec 23. 
 
2. McNamara JR, Warnick GR, Cooper GR. A brief history 
of lipid and lipoprotein measurements and their contribution 
to clinical chemistry. Clin Chim Acta. 2006 Jul 23;369(2):158-
67. Epub 2006 Mar 24. 
 
3. Kimberly MM, Cooper GR, Myers GL. An overview of 
inflammatory markers in type 2 diabetes from the perspec-
tive of the clinical chemist. Diabetes Technol Ther. 2006 
Feb;8(1):37-44. 
 
4. Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander 
RW, Biasucci LM, Catravas JD, Cole TG, Cooper GR, Khan 
BV, Kimberly MM, Stein EA, Taubert KA, Warnick GR, 
Waymack PP; CDC; AHA. CDC/AHA Workshop on 
Markers of Inflammation and Cardiovascular Disease: Ap-
plication to Clinical and Public Health Practice: report from 
the laboratory science discussion group. Circulation. 2004 
Dec 21;110(25):e545-9. 
 
5. Rifai N, Cooper GR, Brown WV, Friedewald W, Havel 
RJ, Myers GL, Warnick GR. Clinical Chemistry journal has 
contributed to progress in lipid and lipoprotein testing for 
fifty years. Clin Chem. 2004 Oct;50(10):1861-70. Epub 2004 
Aug 12. 
 
6. Kimberly MM, Vesper HW, Caudill SP, Cooper GR, Rifai 
N, Dati F, Myers GL. Standardization of immunoassays for 
measurement of high-sensitivity C-reactive protein. Phase I: 
evaluation of secondary reference materials. Clin Chem. 2003 
Apr;49(4):611-6. 
 
7. Blanck HM, Bowman BA, Cooper GR, Myers GL, Miller 
DT. Laboratory issues: use of nutritional biomarkers. J Nutr. 
2003 Mar;133 Suppl 3:888S-894S. 
 
8. Cooper GR, Myers GL, Kimberly MM, Waymack AP. 
The effects of errors in lipid measurement and assessment. 
Curr Cardiol Rep. 2002 Nov;4(6):501-7. 
 
9. Warnick GR, Myers GL, Cooper GR, Rifai N. Impact of 
the third cholesterol report from the adult treatment panel of 
the national cholesterol education program on the clinical 
laboratory. Clin Chem. 2002 Jan;48(1):11-7. 
 
10. Myers GL, Kimberly MM, Waymack PP, Smith SJ, 
Cooper GR, Sampson EJ. A reference method laboratory 
network for cholesterol: a model for standardization and 
improvement of clinical laboratory measurements. Clin 
Chem. 2000 Nov;46(11):1762-72. 
 
11. Caudill SP, Cooper GR, Smith SJ, Myers GL. Assess-
ment of current National Cholesterol Education Program 
guidelines for total cholesterol triglyceride, HDL-cholesterol, 
and LDL-cholesterol measurements. Clin Chem. 1998 Aug; 
44(8 Pt 1):1650-8. 
 
12. Caudill SP, Smith SJ, Cooper GR, Myers GL. Adequacy 
of NCEP recommendations for total cholesterol, 
triglycerides, HDLC, and LDLC measurements. Clin Chem. 
1998 May;44(5):1063-6. 
 
 
 
I look forward to seeing you at the AACC meeting 
in Chicago. 
 
Sincerely, 
 
Gyorgy (George) Csako, MD 
Chair, LVDD, AACC 
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ntroduction 
Higher plasma triglycerides levels and de-
creased high density lipoproteins (HDL)-cho-
lesterol concentrations are usually accompanied by 
the presence of small, dense low density lipo-
proteins (LDL) in the “atherogenic lipoprotein 
phenotype” (ALP): this phenotype is highly ath-
erogenic and its prevalence may suggest higher 
overall burden of atherosclerotic disease than that 
associated with hypercholesterolemia [1,2]. The 
atherogenic dyslipidemia is associated to abdomi-
nal obesity and insulin resistance [3,4] and repre-
sents one of the components of the metabolic 
syndrome [5,6]. It has been also suggested that the 
clinical importance of ALP probably exceeds that 
of LDL-cholesterol, because many more patients 
with coronary artery disease are found to have this 
trait than hypercholesterolemia [7,8]. 
 
As stated by the National Cholesterol Education 
Program Adult Treatment Panel III [9], there is 
evidence that each component of the atherogenic 
lipoprotein phenotype is individually atherogenic, 
but the relative contribution of each component 
cannot be easily determined. Therefore, it has been 
suggested to consider this trait as a whole as a “risk 
factor.” This is supported by data from epidemio-
logical studies considering high-risk populations, 
which showed that the contribution to cardio-
vascular risk of each individual component cannot 
be dissected from the sum of all factors [10,11]. 
 
Also, increasing evidence suggests that the quality 
rather than only the quantity of LDL exerts a great 
influence on cardiovascular risk [1]. In fact, LDL 
particles do not comprise a homogenous popula-
tion, but multiple subclasses with discrete size and 
density, different physicochemical composition, 
metabolic behavior and atherogenicity, with at 
least four major subspecies: large LDL-I, medium 
LDL-II, small LDL-III, very small LDL-IV [12] 
(Figure 1). Based on measurement of peak particle 
diameter or ultracentrifugal density, individuals 
generally cluster into two broad subgroups, the 
majority with a predominance of larger or medium 
sized LDL (pattern A) and a substantial minority 
with a higher proportion of smaller, more dense 
LDL particles (pattern B) [12]. The predominance 
of small, dense LDL, which seems to be associated 
with an approximately three-fold increased risk for 
coronary heart disease (CHD) [1], has been 
accepted as an emerging cardiovascular risk factor 
by the National Cholesterol Education Program 
Adult Treatment Panel III [9]. 
The clinical significance of small, dense LDL 
To date, the association of LDL size with cardio-
vascular diseases has been tested in over 50 
studies, including cross-sectional and prospective 
epidemiologic as well as clinical intervention trials 
[1]. The vast majority of these studies showed a 
strong and significant association of small, dense 
LDL with increased coronary artery disease (CAD) 
risk at univariate analyses. Yet, since LDL size is 
rarely a significant and independent predictor of 
CAD risk after multivariate adjustments for con-
founding variables (including plasma triglycerides 
I
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Figure 1: LDL subclass distribution according to size 
and density (as modified from 61). CAD: coronary 
artery disease. 
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levels and HDL-cholesterol concentrations), it is 
still on debate if the increased atherogenic poten-
tial of small, dense LDL may be a consequence of 
the broader pathophysiology of which these parti-
cles are a part [13-16]. 
 
Several reasons have been suggested for the 
atherogenicity of small, dense LDL. In relation to 
larger, more buoyant LDL: small dense LDL are 
taken up more easily by arterial tissue, have 
decreased sialic acid content and receptor-medi-
ated uptake, as well as increased oxidative suscepti-
bility and reduced antioxidant concentrations [17]. 
Therefore, screening for the presence of small, 
dense LDL may potentially identify subjects with 
higher vascular risk and may contribute in 
directing specific interventions of cardiovascular 
prevention. Increased levels of atherogenic small, 
dense LDL are a feature of subjects at very-high 
cardiovascular risk, such as those with CAD and 
type-2 diabetes [18,19]. Yet, recent studies have 
shown that other categories of subjects at high 
cardiovascular risk may show higher levels of these 
particles. Some authors recently studied subjects 
with clinical forms of non-coronary atheroscler-
osis, including carotid artery disease, peripheral 
arterial disease and abdominal aortic aneurysm, i.e., 
subjects that carry a risk for CAD equal to those 
with established CAD [9]. 
 
Landray et al. in 1998 [20] reported an association 
between small, dense LDL and asymptomatic 
carotid atherosclerosis and this has been con-
firmed by other similar studies in healthy indi-
viduals [21-23]. Other authors found a significant 
relationship between LDL size and the occurrence 
of preclinical and clinical carotid atherosclerosis 
[24-26]. In a clinical trial, Van Tits et al. [27] have 
shown an association between baseline LDL size 
and intima media thickness regression by statin 
therapy (with atorvastatin and simvastatin) and this 
has been confirmed in another study by Wallen-
feldt et al. [28]. We have recently found that 
patients with abdominal aortic aneurysm have a 
smaller LDL size due to increased levels of small, 
dense LDL [29], a finding that was also present in 
subjects with peripheral arterial disease [30], which 
is in line with previous data by O’Neal et al. [31]. 
In other recent studies, elevated levels of small, 
dense LDL were found in patients with different 
metabolic diseases, including polycystic ovary 
syndrome and growth hormone deficiency [32,33], 
as well as in women with gestational diabetes [34]; 
notably, in most of them, the predominance of 
small, dense LDL characterized their type of dys-
lipidemia, alone or in combination with elevated 
triglycerides and reduced HDL-cholesterol con-
centrations. Evidence also suggests that small, 
dense LDL are independently associated with the 
metabolic syndrome. Already in 1995, Haffner et 
al. reported that LDL size was decreased in sub-
jects with multiple metabolic disorders [35]. In a 
recent study, we have extended such observations, 
showing a clear significant association between 
LDL peak particle size and number of compo-
nents of the metabolic syndrome, as assessed by 
the joint American Heart Association/National 
Heart, Lung, and Blood Institute Scientific State-
ment. The importance of LDL particle size as an 
early marker of dyslipidemia and insulin resistance 
is further highlighted by the intriguing finding that 
in school-age children central adiposity was associ-
ated with smaller LDL particle size [36]. 
 
Recent studies [37-40] further suggested that small, 
dense LDL may represent a valuable marker for 
diagnosis and severity of the metabolic syndrome. 
Using the Lipoprint system, Gazi et al. [38] have 
shown that subjects with the metabolic syndrome 
exhibit significantly higher concentrations of small, 
dense LDL than individuals who do not fulfill the 
criteria for such a syndrome. Using a different 
methodology, we recently confirmed that small, 
dense LDL are reduced in the metabolic syndrome 
and further showed an independent predictive role 
for future cardio- and cerebrovascular events [41]. 
 
The clinical impact of the modulation of 
small, dense LDL 
Weight reduction and increased physical activity 
may constitute first-line therapy; in addition, hypo-
lipidemic agents are able to favorably alter LDL 
size and subclasses [42]. Particularly, medications 
with triglycerides-lowering effects shift LDL peak 
size from smaller, more dense to larger, more 
buoyant particles; in fact, reduced availability of 
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triglycerides-rich particles lead to reduced produc-
tion of small dense LDL. This has been shown for 
fibrates and niacin: these substances lower prefer-
entially small dense LDL [43]. Statins potentially 
lower large, medium and small LDL particles, but 
a strong variation has been noticed among the 
different agents. Pravastatin and simvastatin 
showed a limited net effect on LDL subclasses, 
while treatment with fluvastatin and atorvastatin 
resulted more frequently in a beneficial effect; 
promising data were also recently reported by the 
use of rosuvastatin (reviewed in [44,45]. 
 
Other studies have more interestingly investigated 
if the therapeutic modification of LDL size may be 
significantly associated with reduced cardiovascular 
risk. Such investigations used arteriographic 
changes as outcome variables and have reported 
that benefit was concentrated in patients with a 
predominance of small, dense LDL who received 
treatment that tended to lower small dense LDL. 
These studies included the “Stanford Coronary 
Risk Intervention Project” (SCRIP), the “Familial 
Atherosclerosis Treatment Study” (FATS) and the 
“Pravastatin Limitation of Atherosclerosis in the 
Coronary Arteries” (PLAC-I) trial [46-48]. Lova-
statin was administered in the SCRIP (with bile 
acid-binding resins, niacin or fibrates) and in the 
FATS (with colestipol, versus niacin and colesti-
pol), pravastatin was used in the PLAC-I. 
 
The therapeutic modulation of LDL size was 
significantly associated with reduced cardiovascular 
risk at univariate analysis. In addition, at multi-
variate analyses with adjustments for confounding 
factors, changes in LDL size by drug therapy were 
the best correlates of changes in coronary stenosis 
in FATS [48]. In PLAC-I, using logistic regression 
models that adjusted for lipid levels and other 
confounding factors, elevated levels of small LDL 
were associated with a nine-fold increased risk of 
CAD progression in the placebo group [46]. All 
these data seem to suggest that the therapeutic 
modification of LDL size may be significantly 
associated with reduced cardiovascular risk, even 
after multivariate adjustment for confounding fac-
tors. In addition, as already reported [49], although 
not directly demonstrated, the modulation of LDL 
size with fibrates probably contributed to the re-
duction of cardiovascular risk in two clinical trials, 
the “Helsinki Heart Study” and the “Veterans Af-
fairs High-density Lipoprotein Cholesterol Inter-
vention Trials Study Group” (VA-HIT) [50-52]. 
 
Yet, although fibrates are more powerful than 
statins in improving LDL quality, existing evidence 
suggest that statins are more powerful agents in 
reducing cardiovascular morbidity and mortality. 
Fenofibrate seems to be very effective in lowering 
small dense LDL, but the FIELD study [53,54] 
showed no significant reduction in primary end 
point in type-2 diabetics randomized to receive 
fenofibrate or placebo. In this study, triglycerides 
were reduced from 1.95 to 1.47 mmol/l; as it is 
expected that LDL distribution improves below 
the triglycerides threshold of 1.5 mmol/l, the find-
ings of the FIELD study may argue against the 
concept that increasing LDL size is a major modu-
lator of cardiovascular risk. In addition, in a subset 
statin-free cohort of the FIELD study, it was 
recently shown that fenofibrate produced a clear 
shift in HDL subspecies towards smaller more 
atherogenic particles [55]. 
 
Conclusions 
Small, dense LDL are atherogenic particles. Yet, 
the small dense phenomenon applies to all lipo-
protein particles, so that small dense chylomicron 
remnants, as well as small dense HDL may con-
tribute to the atherogenic nature of the profile, but 
there is also evidence that large cholesterol-rich 
particles contribute to cardiovascular risk, such as 
large LDL particles [13]. This is further compli-
cated by the fact that at the same level of LDL-
cholesterol, higher-risk individuals with a predomi-
nance of small, dense LDL have significantly more 
particles than those with a predominance of larger, 
more buoyant LDL. The number of LDL particles 
in plasma is potentially important, because the 
arterial walls are exposed to these particles, and an 
increased number might increase atherogenicity 
independently of particle size. 
 
Is higher risk of individuals with a predominance 
of small, dense LDL attributable to the fact that 
they have more LDL particles in total, or does the 
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smaller size contribute independently to CHD 
risk? Assessment of LDL size and subclasses does 
not provide information about the number of 
LDL particles, which has been usually estimated by 
measuring apoB concentrations, due to the pres-
ence of one apoB-100 molecule per LDL. Higher 
LDL particle concentrations seem to be very 
important in determining cardiovascular risk; how-
ever, few studies have assessed if the quantity 
rather than the quality of small, dense LDL may be 
stronger associated with that risk. In these studies, 
the number of total and smaller LDL particles has 
consistently been shown to be a significant and 
independent predictor of cardiovascular risk fol-
lowing multivariate adjustment for lipid variables. 
 
In summary, such data underline the clinical im-
portance of assessing LDL particle size and num-
ber in order to adequately establish cardiovascular 
risk. Since increasing evidence from prospective 
studies suggest the superiority of apoB or LDL 
particle number over traditional LDL-cholesterol 
measurement for the assessment of cardiovascular 
risk, different position statements have advocated 
in the last years a more routine measurement of 
apoB in clinical practice [56-59]. By contrast, the 
assessment of lipoprotein subclasses, such as 
small, dense LDL, should involve the use of well-
established laboratory methods and this signifi-
cantly limits its use in clinical practice; surrogate 
markers of small, dense LDL may be used in large 
clinical studies, but they should be interpreted with 
caution as they may give misleading results [60]. 
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n the beginning there was darkness and from 
the darkness emerged a fatty substance that 
was unknown among men. Scientists studied 
the substance and found it present in the cells of 
animals and humans. An abnormal amount of this 
chemical in both humans and animals was assoc-
iated with an increased risk of heart disease and 
sudden death. It was discovered that this fatty 
material was deposited in large quantities on the 
surface of the vessels. These vessels are called 
arteries and the surface is coated with endothelial 
cells where the build up of fatty substance is called 
plaque. Scientists worked feverishly (sweaty) and 
tirelessly (tread was running low) to identify this 
unknown substance. Soon mad scientists were 
successful at identifying this substance that was 
responsible for destroying lives at an early age and 
it was called cholesterol. Before long, a special 
group of individuals was united with the task to 
learn more about this substance and to distribute 
pertinent information to all its members. Thus, 
was born the Lipids and Lipoproteins Division of 
AACC and the The Fats of Life, a newsletter to keep 
the membership informed of news and events that 
were happening in the world of lipids. 
 
Ok, so this might be a little stretch of the imagi-
nation to believe that the above has any shred of 
truth as to how and when the L&LD and The Fats 
of Life were brought into the world of AACC. 
Actually, an application was authored by several 
key individuals (the names my weak mind recalls as 
key contributors in this effort include GR War-
nick, JD Artiss, Bennie Zak, HK Naito, DA 
Wiebe, and GR Cooper) and the application was 
submitted to AACC for consideration of a new 
AACC division on March 31, 1986. The Board of 
Directors of AACC accepted and approved the 
provisional status of L&LD at their December 
1986 meeting. In 1989, the term “provisional” was 
removed and the L&LD was an official division of 
AACC. Twenty years – where has the time gone? 
The early leadership of L&LD included G. Russell 
Warnick as Chairman, myself as Secretary, Joseph 
D. Artiss as Treasurer, and Herbert K. Naito as 
Member-at-Large. My memory remains cloudy as 
to exactly how these individuals were selected to 
these lofty positions, but I am almost certain that 
there was not an open election process involved. 
Arm-twisting, probably, but certainly my vote 
wasn’t counted. As secretary, I also inherited the 
task to produce and edit our newsletter, The Fats of 
Life. The aforementioned management team re-
mained intact for the three years that L&LD was 
designated as a provisional division of AACC. 
Elections were held during the fall of 1989 and we 
elected Chair-elect, Secretary and a Treasurer (not 
sure what happened to the Member-at-Large). 
Therefore, our leadership counsel was now com-
posed of a Past-Chair (Russ), Chair (myself), 
Chair-elect (Gary Myers), Secretary (Judith McNa-
mara), and Treasurer (Joseph Artiss). This is where 
my memory cells have failed me again because I’m 
not sure whether the Chair was truly elected or 
appointed and only our Chair-elect was selected by 
our membership. Another significant change in 
our leadership roles had taken place during the 
summer of 1988, Nader Riafi, a clinical chemist at 
Children’s Hospital in Washington D.C., accepted 
the duties and responsibilities as Editor for The 
Fats of Life (I wonder if this could lead to bigger 
and better things to come?). These were the early 
days of L&LD and our Division was off to a fast 
start. 
 
Timing of the formation of the L&LD coincided 
with a couple of major events that occurred 
around this same timeframe. First, the results of 
the NIH-funded Lipid Research Clinic’s primary 
prevention trial were published in 1984. The LRC 
study clearly demonstrated that lowering plasma 
cholesterol in men reduced their risk for a cardio-
vascular event. Lowering total cholesterol by 1% 
reduced the individual’s risk of CHD by 2%, an 
I
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outcome that supported the claims that cholesterol 
played a major role in the development of cardio-
vascular disease. Next, NIH established the 
National Cholesterol Education Program (NCEP). 
NCEP was given several goals and the three 
prominent ones were to: 1) establish an Adult 
Treatment Panel that developed uniform guide-
lines for physicians to use when treating patients 
with hypercholesterolemia, 2) increase the public’s 
awareness about the health concerns related to 
hypercholesterolemia, and 3) improve the labora-
tory performance for measuring cholesterol. This 
last goal was one that L&LD and our members 
would have a significant impact and participation 
to ensure its success. 
 
Many of our members played key leadership roles 
on committees, such as the NCEP Laboratory 
Standardization Panel, or as part of the Cholesterol 
Method Reference Laboratory Network (CMRLN) 
that provided the basis and foundation to improve 
the routine methods used to monitor patient’s 
cholesterol status. Our L&LD had a major role in 
supporting forums at national AACC meetings 
where many of the issues related to cholesterol or 
lipid analyses were discussed openly to seek ways 
in which improvement could be achieved. In fact, 
the first issue, Volume I of The Fats of Life, pub-
lished June 1987, promoted an L&LD conference 
to be held on Sunday afternoon at the national 
AACC meeting in San Francisco. The title of the 
conference was “Issues of Lipid Standardization 
and Reference Materials.” The meeting was divid-
ed into two sessions; in the first session speakers 
were invited from NCEP (Herb Naito), CDC 
(Gary Myers), CAP (Al Hartmann), the National 
Reference System – Cholesterol (Ray Vanderlinde), 
and Russ Warnick to discuss the needs to improve 
cholesterol laboratory performance. During the 
second session, speakers representing industry, 
such as Nathan Gochman (Beckman Instruments), 
Wendell O’Neil (DuPont), Jack Levine (Techni-
con), Robert Bodden (American Dade) and Neil 
Greenberg (Eastman Kodak), discussed issues 
related to their own instruments. The conference 
was extremely well attended and through L&LD’s 
efforts the conference brought together major 
players that were needed to put their resources 
together to improve our laboratories’ ability to 
provide precise and accurate measurements of 
serum cholesterol. These manufacturer workshops 
became quite popular at AACC meetings and 
during the next few years our division was joined 
by NCCLS to co-sponsor the events. The first 
four workshops dealt with issues related directly to 
cholesterol analysis and ways in which our various 
laboratory methods could be improved. Manufac-
turers, government agencies (CDC, NIST, FDA), 
and clinical laboratory organizations (AACC, CAP, 
NCCLS) played important roles in these activities 
to overcome some of the issues related to choles-
terol testing and cholesterol standardization. Our 
Division was instrumental in bringing together key 
individuals and groups with a common goal to 
overcome specific issues related to generating 
reliable cholesterol data for patients. 
 
One yardstick to judge the success of an AACC 
division is the growth of the membership over the 
first few years when the division was given pro-
visional status. Had the AACC members failed to 
sign up as members of the L&LD and shown little 
interest in what our Division had to offer, then it is 
unlikely that the Board of Directors would have 
granted permanent status for our Division. Our 
growth during these early years was as hoped and 
our Division grew from an initial membership of 
207 in 1987 to 383 in 1988 and 458 by 1989. I 
suspect this helped influence the final decision to 
change our status as a provisional group. Today, 
our membership of the Lipoproteins and Vascular 
Diseases Division is close to 485 members, thus 
there are still quite a few individuals that find 
membership in our group to be worthwhile. 
 
So where did we come up with the name for our 
newsletter? As secretary for our Division during 
those early years, I was assigned, or given the 
opportunity, to produce a newsletter for our 
members. Using a newly acquired Macintosh 512K 
computer and its graphics capability, a newsletter 
(Volume 1, number 1) was sent to all members 
during June 1987. 
 
I used “Fats of Life” as the name for our newsletter. 
However, I would not be honest if I took sole 
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credit for this. Actually, I was taking a biochem-
istry class several years earlier at the University of 
Iowa where an instructor had used this phrase to 
introduce a chapter on lipids. I’m not sure why the 
phrase stuck with me so long, but it seemed to “fit 
like a glove.” A copy of this first newsletter ap-
pears in this issue of the FATS and will, therefore, 
find a place in our archives for anyone wishing to 
see how far we have advanced. The initial news-
letter doesn’t come close the quality or profession-
alism that goes into generating our current product 
thanks to the contribution of the individuals that 
serve on the Editorial Board for the Newsletter. 
 
Next question: who is responsible for the original 
logo for our Division? The answer to this question 
can be found be found in Volume 1, Number 2 
edition of our newsletter, published in January 
1988. Figure 1 shows our first logo, which was 
introduced in the second newsletter, and it was 
acknowledged that Donald Renaud from Ottawa, 
Ontario designed it. 
 
 
This logo was prominently displayed on the 
majority of our newsletters and was also placed on 
awards that our Division bestowed on deserving 
members. Figure 2 is a proposed logo that ranked 
second, but was never used. A few of the other 
logos that have been used by our Division are also 
shown below (Figures 3 and 4). 
 
Clearly our Lipoproteins and Vascular Diseases 
Division has and continues to be active in the 
areas of lipids and lipoproteins plus numerous 
other AACC activities. I can look back on my own 
career and appreciate how valuable and enriching 
my membership in our Division has been for my 
Figure 1. First L&LD logo, which was introduced in the 
second Fats of Life newsletter. 
Figure 3. Logo associated with our Newsletter during 
the late 1990s early 2000s, and still used today in 
the footer. 
Figure 2. A runner up for the first logo of our Division 
(unknown submission). 
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professional advancement. I have developed 
special friendships and participated in unique op-
portunities over the last several years and many are 
directly related to my involvement in our organi-
zation. I encourage all our members, young and 
old to get involved and active in our Division – the 
benefits and rewards will be amazing. 
 
Figure 4. Current logo of the Lipoproteins and 
Vascular Diseases Division. 
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Executive Meeting Teleconference 
Wednesday, April 8, 2009 
 
Attendees: Gyorgy Csako (Chair), John Contois (Editor, Fats of Life), Faith Clendenen (Secretary), Dan 
Hoefner (Information Officer), Amar Sethi, Joe McConnell (Past Chair), Russell Warnick (Editor, Fats of 
Life), Rose Romeo (Treasurer) 
 
 
Agenda: 
 
1. Approval of minutes from November 25, 2008 (Teleconference). Approved as submitted. 
 
2. The Fats of Life 
Spring Issue by April 15th, Guest Editorial by Don Wiebe to be moved to Summer (see below). Minutes 
from the Executive Board Meeting must be included as required by the By-Laws. Faith to get minutes 
to John Contois before April 15th. Three other articles scheduled but not yet submitted. 
Summer issue dedicated to our 20th anniversary. Trying to get a history of the division from Don Wiebe. 
Articles will be submitted that reflect the history and contributions of the Division, including something 
from Gerald Cooper. Get a list of founders of the division and include that in the FOL and invite them to 
the Monday Night meeting. Include pictures of early meetings if there are any available. 
 
3. Annual Division Feedback for LVDD from Steve Kazmierczak, PhD, DMG Chair. Very encouraging 
information. The accompanying report provides a summary of our division’s strengths from the DMG 
perspective and outlines areas of opportunity for 2009. We are asked to consider the “challenges and 
opportunities” section of the attached report as you make plans for next year. 
 
4. Annual Meeting 
Contributions for the Monday Night Meeting. Ortho to give $10000 contribution for the Monday Meeting. 
Helena Labs has already donated $1000 to the division; check should be at National. They have requested that 
CE’s be available for this meeting; (Faith and Penny working on this.) Dinner fee is $50 but cost is 
$100/head. It is being limited to members only. In view of the generous donations from Ortho and Helena, 
the meeting size could be expanded. Comment (from Penny Jones): Our online registration system cannot 
identify membership at the division level. That means we will not be able to allow online registration for the 
Monday dinner and Lipoproteins forum. Registration for these events will have to be by paper. Also, to 
prevent confusion (since non division members have been allowed to participate in the past), our Customer 
Service Manager recommends not putting this on the Annual Meeting registration order form. That means 
promoting it separately to division members only.” How this would be handled was not discussed during the 
teleconference. 
 
 
Minutes, AACC Lipoproteins and Vascular Diseases Division
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Meeting rooms, already arranged, are listed here: 
 
Sunday Board and Business Meeting: Sunday, July 19, 8:00am—11:00am, Hyatt Regency Chicago Hotel 
(Columbian Room) 
 
Monday Dinner Meeting: Current Topics in Cardiovascular Disease, Monday, July 20, 5:30pm—9:30pm, 
Hyatt Regency Chicago Hotel (Columbus Hall A, B, C, D) 
 
Tuesday Night Dinner: INTERNATIONAL LIPOPROTEIN STANDARDIZATION FORUM, 
Tuesday, July 21, 6:00pm—9:30pm, Hyatt Regency Chicago Hotel (Columbus Hall K, L) 
 
5. Annual Business Meeting as required by By-Laws: Sunday morning meeting or Monday night 
meeting? Room size limited for Sunday morning, but Monday night too busy. The consensus is to use 
Sunday morning meeting as the annual business meeting, increase room size and food obtained. 
Unanimously approved. 
 
6. Awards: 
2009 Zak Award (Contributions to Science): Joe McConnell 
Cooper (Contributions to Technology) Award is due in 2010 
2009 Pacific Biometric Research Foundation Award: Dr. Chong Yuan (California) 
Award for FOL Best Article in 2008: To be decided by Nomination Committee based on 5 candidate 
articles selected by editors. Need this by May 1st. 
Our travel award for young foreign clinical chemists has been discontinued due to budget constraints. 
LVDD poster awards. Need to arrange to do the poster awards. Amar Sethi has volunteered to help with 
the poster award. We will make the decision based on the abstracts and have the awards (ribbons) on the 
posters and checks in advance, if possible. Rose will follow up on ribbons and timing of checks. 
Faith to send awardee info to Rose, received from Gyorgy. 
 
7. Accent Credit for Annual Meeting: Faith and Penny to get in place. 
 
8. Elections in 2009: 
This year Nominating Committee members are up for election. Need names for nominating committee, and 
Treasurer and Secretary are technically both in their second year, although they are not currently elected in 
alternate years. Gyorgy will send email of rules regarding alternating years of Treasurer and Secretary. 
Secretary (Faith) has offered to extend an additional year, and ask for one of the Nominating Committee to 
extend a year also. Unanimously approved. Urgently needed nominations for Treasurer and Nominating 
Committee member. By-laws require two names for each position. 
 
10. .Next Teleconference: Need additional Teleconference in mid-May. Open items to be discussed: 1) 
shared meeting with a local section, possibly in the fall, 2) discuss changes to By-Laws, 3) Names for 
nominations, and 4) 20th Anniversary issues. Please review the By-Laws (attached) before the next meeting. 
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LIPOPROTEINS and VASCULAR DISEASES DIVISION BY-LAWS 
 
ARTICLE I. Name 
The name of this organization will be the Lipoproteins and Vascular Diseases Division (referred to below as 
DIVISION) of the American Association for Clinical Chemistry (referred to below as AACC). 
 
 
ARTICLE II. Purpose 
The purpose of the DIVISION will be the provision of a focus for interaction among AACC Members with interests in 
lipids, lipoproteins and vascular diseases and a forum for communication among laboratorians, clinicians, other 
scientists and representatives of industry; promotion of activities which lead to improvements in the general level of 
knowledge in measurement technology, in standardization of methods, and in interpretation/usefulness of 
lipid/lipoprotein results; and enhancement of the professional image and status of the AACC. 
 
 
ARTICLE III. Methods and Activities 
A. The DIVISION will support and facilitate programs which will help to achieve the stated purposes. 
 
B. The DIVISION will review/evaluate existing and new lipid/lipoprotein methodologies/technologies and provide 
information to the membership. 
 
C. The DIVISION will submit suggestions for educational sessions to the Organizing Committee of each Annual 
Meeting of the AACC. 
 
D. The DIVISION will cooperate with local sections, other divisions, and other professional groups to co-sponsor 
meetings and to work jointly for the advancement of science, medicine, and technology. 
 
E. The DIVISION will assist or coordinate assignments for speakers and disseminate educational materials dealing 
with various aspects of the lipid and lipoprotein field to groups wishing these services. 
 
F. The DIVISION will publish a newsletter providing information about DIVISION meetings, significant events, and 
selected topics of current interest. This newsletter will be provided to all DIVISION Members. 
 
G. The DIVISION will hold a business meeting at the Annual AACC Meeting each year, with opportunity for 
discussion and review of activities. 
 
 
ARTICLE IV. Membership 
Anyone who is a current Member of the AACC as defined by the Association Bylaws, Article I, may become a 
DIVISION Member by contacting the DIVISION or the AACC National Office and by paying the DIVISION dues. 
 
 
ARTICLE V. Officers 
A. The officers of the DIVISION will be Members in good standing of the AACC and the DIVISION. Only officers 
and their delegates may represent the DIVISION in official capacities. 
 
B. The officers of the DIVISION will be a Chair, who will serve two (2) years; a Chair-Elect, who will serve two (2) 
years and be designated as Chair for the following two (2) years; a Secretary, a Treasurer and an Information 
Officer, each of whom will serve for two (2) years. The Chair-Elect will be elected every other year and the 
Secretary and Treasurer will be elected in alternate years and will not serve for more than two (2) consecutive 
terms, or four (4) consecutive years. The Information Officer will be appointed by the Chair. The Chair will not be 
eligible for re-election to the office of Chair-Elect until one year has lapsed since his/her last term of office. The 
powers and duties of the officers will be those usually vested in their respective positions or specified by the 
Bylaws. 
 
C. The duties of the various officers will be as follows: 
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1. Chair 
a. Function as the executive officer for the DIVISION. 
b. Organize and preside at all official meetings of the DIVISION. 
c. Coordinate Committee and general DIVISION activities. 
d. Appoint Committee chairs subject to the approval of the Executive Committee. 
e. Coordinate preparation of the annual report and the annual budget. 
f. Serve as an ex-officio member of each Committee. 
g Serve as Chair of the Nominating Committee. 
 
2. Chair-Elect 
a. Preside at meetings in the absence of the Chair. 
b. Act for the Chair in case of his/her absence or disability. 
c. Serve as Chair of the Program Committee. 
d. Direct long-range planning activities of the DIVISION. 
 
3. Secretary 
a. Keep minutes of all meetings of the DIVISION at which business is conducted, and submit them to the 
Chair for approval. 
b. Maintain the minutes of all meetings as a record and transmit them to the succeeding Secretary. 
c. Submit approved minutes to the Newsletter Editor for publication in the newsletter. 
d. Carry out correspondence of the DIVISION as delegated by the Chair. 
e. Distribute notices of meetings, ballots, and election results to the membership and receive completed 
election ballots. 
f. Assist the Chair with the preparation of the annual report. 
 
4. Treasurer 
a. Receive and distribute funds authorized in the DIVISION budget. 
b. Maintain accurate and current records of all credits, debits, and balances and transmit them to the 
succeeding Treasurer. 
c. Present a financial report of receipts, disbursements, and current balances at official meetings. 
d. Assist the Chair with the preparation of the annual budget and report. 
 
5. Information Officer 
a. Serve as DIVISION Web Master. 
b. Collaborate with Newsletter Editor on projects as needed. 
c. In conjunction with the AACC, keep consumer web page current. 
 
ARTICLE VI. Committees 
 
Standing Committees will include the Executive Committee, the Program Committee, the Nominating Committee, 
and the Membership Committee. 
 
A. Executive Committee 
1. Will consist of the DIVISION Chair, Chair-Elect, Secretary, Treasurer, and Information Officer. 
2. Will have authority to act on all matters concerning the DIVISION. 
3. Will meet at least once a year. 
4. Will consist of a quorum, necessary to conduct DIVISION business, of at least three (3) of the five (5) members. 
5. May invite the Newsletter Editor and the Chairs of ad hoc committees to participate as non-voting 
representatives. 
 
B. Program Committee 
1. Will consist of a Chair, who will be the current Chair-Elect of the DIVISION, and members to be appointed 
annually as deemed necessary by the Committee Chair. 
2. Will plan, schedule, and coordinate workshops, seminars and other educational activities of the DIVISION. 
3. Will provide a summary of activities to the DIVISION Chair for inclusion in the annual report. 
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C. Nominating Committee 
1. Will consist of a Chair, who will be the Chair of the DIVISION, and two elected Members. The elected Members 
will serve for two (2) years; one Member will be elected each year from a list of two (2) candidates submitted by 
the Nominating Committee as described in Section C, 3 below. Members of the Nominating Committee may not 
succeed themselves and are ineligible to be nominated as an officer, for a period of one (l) year following the 
end of their term on the Committee. 
2. Will prepare a slate of candidates for the elected offices as described in ARTICLE V. Candidates will have given 
prior consent to serve, if elected. 
3. Will report the slate of nominees to the DIVISION Secretary by March 15th of each year. 
4. Initial Nominating Committee will be selected by the Executive Committee of the Provisional Division. 
 
D. Membership Committee 
1. Will consist of a Chair, who will be appointed by the DIVISION Chair with the approval of the Executive 
Committee, and members to be appointed annually as deemed necessary by the Committee Chair. 
2. Will maintain an accurate list of names and addresses of all members. 
3. Will devise and implement strategies to recruit new members and retain current members. 
4. Will provide a summary of activities to the DIVISION Chair for inclusion in the annual report 
 
E. Finance Committee 
1. Will consist of a Chair, who will be appointed by the DIVISION Chair with the approval of the Executive 
Committee, the DIVISION Treasurer, and members to be appointed annually as deemed necessary by the 
Committee Chair. 
2. Will solicit funds to support DIVISION activities and will recognize donors. 
 
F. Other Committees 
Other ad hoc committees will be convened as deemed necessary. The Chair of each committee will be appointed 
by the DIVISION Chair with approval from the Executive Committee. 
 
 
ARTICLE VII. Terms of Office, Elections, and Vacancies 
 
A. Terms of Office 
Terms of office will begin on January 1 and end on December 31 of each year. 
 
B. Elections 
1. Elections will be by mail or electronic ballot, conducted so as to maintain secrecy. 
2. The Chair of the Nominating Committee will notify the Secretary of the slate of candidates by March 15th of each 
year. The nominees will be those members selected by the Nominating Committee and who have agreed to 
serve prior to having their names placed on the ballot. 
3. The candidates will provide biographical sketches for the ballots to the Secretary by April 1. 
4. The Secretary will distribute by May 1 a ballot, consisting of a slate prepared by the Nominating Committee, to 
each member of the DIVISION. This ballot will show the positions to be filled, the nominees for each office, and 
a provision for write-in votes. 
5. The deadline for receipt of valid ballots will be June 1. Completed ballots will be received by the DIVISION 
Secretary and opened and tallied by two non-candidates appointed by the Secretary. 
6. Nominees receiving a plurality of votes will be elected. In the event of a tie vote, the election will be decided by 
secret ballot of the Executive Committee. 
7. The Secretary, by June 15, will then report the results to the DIVISION Chair, who will notify the nominees. 
8. The Secretary will notify the Executive Committee, the membership, and the National Office. 
9. In the event that an officer is not elected by January 1, the preceding officer will continue to serve until relieved 
by the duly elected succeeding officer. 
 
C. Vacancies 
1. Resignation of officers, except the Chair, will be submitted in writing to the Chair. The resignation of the Chair 
will be submitted in writing to the Executive Committee. 
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2. In the event of a vacancy in the office of Chair, the Chair-Elect will succeed the Chair for the remainder of the 
unexpired term and for the following fiscal year. In the event of a vacancy in the office of Secretary or Treasurer, 
or among the elected Members of the Nominating Committee, the incumbent Executive Committee will appoint a 
qualified Member to discharge the duties of that office until January 1st following the next regularly scheduled 
election to fill that vacancy. In the event of a vacancy in the office of Chair-Elect, the Nominating Committee will 
transmit within thirty (30) days of the vacancy to the Secretary, a list of nominees for election. This election 
process will be completed as quickly as practical, as described in ARTICLE VII, Section B. The Chair will fulfill 
the Chair-Elect's responsibilities in the interim. 
3. An officer may be impeached following, first, a majority vote by the Executive Committee, and second, a mail-
ballot vote by the Membership. A two-thirds majority of the votes cast is required to effect the removal from office 
of one of the elected officers. 
 
 
ARTICLE VIII Finances 
 
A. The fiscal year of the DIVISION will coincide with that of the AACC, beginning on January 1, and ending on 
December 31. 
 
B. DIVISION dues, established by the Executive Committee, will be collected by the National Office with regular 
AACC membership dues. 
 
C. The DIVISION will follow the rules established by the AACC Finance Committee for expenses (living and travel), 
honoraria (amount and eligibility), and registration fees. 
 
D. The Chair and Treasurer of the DIVISION will prepare an annual report as requested by the National 
Organization to be submitted to the AACC Liaison and Board of Directors through appropriate channels. The 
report will include the status of the DIVISION, activities and accomplishments, financial notation of sources of 
revenue and purposes for which they were used and the organizations to be solicited in the coming year. 
 
E. In the event that the DIVISION is dissolved, all funds remaining after the payment of debts will be transferred to 
the AACC. In no event will any funds of the DIVISION inure to the benefit of any DIVISION Member either during 
the life of the DIVISION or after its dissolution. 
 
ARTICLE IX. Adoption and Amendment to the Bylaws 
 
A. Amendments of these Bylaws may be proposed by a majority vote of the Executive Committee, by a petition 
signed by at least 10% of the Members in good standing, or by a duly passed motion at any official business 
meeting. Proposals for adoption or amendments of the Bylaws will be distributed to each Member in good 
standing by the Secretary within 45 days of receipt. 
 
B. Adoption and amendments of the Bylaws will require an affirmative vote by two-thirds of the votes received. If 
the proposal does not receive the required number of votes within 30 days after the proposal is distributed, then 
such proposal will lapse. 
 
C. These Bylaws will become effective at the time of their adoption. 
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Gyorgy Csako, MD 
 
Title: Low-density lipoprotein cholesterol concen-
trations and death due to intraparenchymal hemor-
rhage: the Ibaraki Prefectural Health Study. 
Authors: Noda H, Iso H, Irie F, Sairenchi T, 
Ohtaka E, Doi M, Izumi Y, Ohta H. 
Journal: Circulation. 2009 Apr 28;119(16):2136-
45. Epub 2009 Apr 13. 
Comment: Since most of our effort involves lipid 
lowering, it is interesting to note that low lipid 
levels may not always be advantageous. A possible 
association between low total cholesterol levels 
and increased risk of intraparenchymal hemor-
rhage (hemorrhagic stroke), which has a low sur-
vival rate and a high risk of disability, was reported 
first 3 decades ago. Since then, several, but not all, 
studies confirmed such an association. Hemor-
rhagic stroke has unique pathological and epidemi-
ological characteristics that distinguish it from 
coronary heart disease (CHD). It is caused pri-
marily by hypertension and, as observed earlier, 
possibly by low concentrations of low-density 
lipoprotein-cholesterol (LDL-C). This large Japa-
nese population-based study cohort study further 
examined the association between low levels of 
LDL-C and risk of intraparenchymal hemorrhage. 
A total of 30,802 men and 60,417 women, 40 to 79 
years of age with no history of stroke or coronary 
heart disease, completed a baseline risk factor 
survey in 1993 under the auspices of the Ibaraki 
Prefectural Health Study. Systematic mortality 
surveillance was performed through 2003, and 264 
intraparenchymal hemorrhage deaths were iden-
tified. LDL-C levels were calculated with the 
Friedewald formula. Persons with LDL-C >140 
mg/dL had half the sex- and age-adjusted risk of 
death due to intraparenchymal hemorrhage of 
those with LDL-C <80 mg/dL. After adjustment 
for cardiovascular risk factors, the multivariable 
hazard ratio compared with persons with LDL-C 
<80 mg/dL was 0.65 (95% CI 0.44-0.96) for those 
with LDL-C 80 to 99 mg/dL, 0.48 (0.32-0.71) for 
100 to 119 mg/dL, 0.50 (0.33-0.75) for 120 to 139 
mg/dL, and 0.45 (0.30-0.69) for >140 mg/dL. 
These inverse associations were not altered 
substantially after the exclusion of persons with 
hypertriglyceridemia, after analysis with a Cox pro-
portional hazard model with time-dependent co-
variates, or in sensitivity analysis for the potential 
effect of competing risks. There was a U-shaped 
relationship between LDL-C and combined death 
due to intraparenchymal hemorrhage and CAD, 
with a nadir at LDL-C levels of 120-139 mg/dL 
(3.10-3.61 mmol/L) because these 2 outcomes 
have an opposite direction in the association with 
LDL-C. The authors concluded that low LDL-C 
levels indeed are associated with elevated risk of 
death due to intraparenchymal hemorrhage and 
suggested that this relationship likely is causal. An 
accompanying editorial (see below) further ana-
lyzed the results of this study and its relevance to 
cholesterol (LDL-C)-lowering therapy. 
 
Title: The complex relationship between choles-
terol and brain hemorrhage. (Editorial on the 
article by Noda et al. Circulation. 2009 Apr 28; 
119(16):2136-45) 
Author: Goldstein LB. 
Journal: Circulation. 2009 Apr 28;119(16):2131-3. 
Comment: Commenting on the findings of Noda 
et al., Dr. Goldstein pointed out that the relation-
ship between lipid levels and stroke is complex: 
although low, usual total cholesterol and LDL-C 
levels in persons free of cardiovascular disease or 
stroke appear to be associated with a higher risk of 
brain hemorrhage, this does not mean that treating 
patients with vascular disease with lipid-lowering 
medications increases risk. Even achieving very 
low levels of LDL-C (i.e., <40 mg/dL or <64 
mg/dL) with statins in patients with coronary 
heart disease was not associated with an increased 
risk of brain hemorrhage. On the other hand, the 
situation is somewhat more complicated in pa-
tients with a prior history of stroke in whom the 
overall treatment-related benefit in reducing the 
risk of the primary end-point (fatal or non-fatal 
stroke) was partially attenuated by a treatment-
related increase in brain hemorrhage. Thus, the 
relationship between statin therapy and the risk of 
brain hemorrhage may be different in patients with 
a history of cerebrovascular disease (who overall 
still benefit from statin treatment) compared with 
those without such a history. While the epidemio-
Literature Review
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logical data based on usual total cholesterol and 
LDL-C levels suggest an association between low 
levels and increased risk of brain hemorrhage, 
there is no evidence of a relationship between 
cholesterol levels and bleeding risk in patients with 
coronary heart disease whose lipid levels have been 
lowered medically. Dr. Goldstein also emphasized 
that establishing causality based on statistical 
associations from observational studies is always 
hazardous. In fact, the lack of a relationship be-
tween low, usual total cholesterol and LDL-C and 
higher risk of brain hemorrhage in persons whose 
total cholesterol and LDL-C have been lowered 
therapeutically argues against causality. 
 
Title: Modification of the association between 
alcohol drinking and non-HDL cholesterol by 
gender. 
Authors: Wakabayashi I, Groschner K. 
Journal: Clin Chim Acta. 2009 Jun 27;404(2):154-
9. Epub 2009 Mar 29. 
Comment: A possible role of alcohol consump-
tion for reducing cardiovascular risk has been long 
debated. The authors of this article studied the 
relationship between habitual alcohol drinking and 
serum non-HDL cholesterol (non-HDL-C, a 
strong predictor of cardiovascular diseases) in a 
Japanese population. Healthy male subjects (n = 
27,005) and female subjects (n = 16,805) were 
divided into 5 groups by average daily ethanol 
intake. Serum non-HDL-C level and prevalence of 
serum high non-HDL-C (≥170 mg/dL) were 
compared among the groups. It was found that 
non-HDL-C level and prevalence of high non-
HDL-C become lower as alcohol intake increases. 
The threshold alcohol intake in the drinker groups 
showing significantly lower non-HDL-C level and 
significantly lower prevalence of high non-HDL 
cholesterol, compared with those in non-drinkers, 
was lower in women (<10 g/d) than in men (≥10 
and <20 g/d). Odds ratios of each drinker group 
vs. the non-drinker group for high non-HDL-C 
became lower as alcohol intake increased. The 
odds ratio of each drinker group vs. the non-
drinker group for high non-HDL-C tended to be 
lower in women than in men. Thus, even light 
drinking is sufficient to significantly lower serum 
non-HDL-C and that this effect of alcohol 
drinking on non-HDL-C is more pronounced in 
women than in men. 
 
Title: The association of 83 plasma proteins with 
CHD mortality, BMI, HDL- and total-cholesterol 
in men: applying multivariate statistics to identify 
proteins with prognostic value and biological 
relevance. 
Authors: Heidema AG, Thissen U, Boer JM, 
Bouwman FG, Feskens EJ, Mariman EC. 
Journal: J Proteome Res. 2009 Jun 5;8(6):2640-
2649. Epub 2009 Apr 7. 
Comment: Recent technical advances in proteo-
mics such as multiple assays provide the oppor-
tunity to simultaneously measure the concentra-
tions of a large number of proteins in plasma. This 
enables researchers to study the relationships of 
groups of proteins with the outcome of interest. In 
this study, the authors applied the multivariate 
statistical tool Partial Least Squares (PLS) to 
analyze the relative importance of 83 plasma pro-
teins in relation to coronary heart disease (CHD) 
mortality and the intermediate endpoints body 
mass index, HDL-cholesterol and total cholesterol. 
PLS takes the information of all proteins into 
account with respect to a certain end-point and is 
able to handle not only large numbers of variables 
in moderate to small sample sizes, but also the 
presence of multicolinearity among the proteins. 
From a Dutch monitoring project for cardiovascu-
lar disease risk factors men who died of CHD 
between initial participation (1987-1991) and end 
of follow up (January 1, 2000) (N=44) and 
matched controls (N=44) were selected. Baseline 
plasma concentrations of proteins were measured 
by a multiplex immunoassay. Applying PLS, the 
authors identified 15 proteins with prognostic 
value for CHD mortality and sets of proteins 
associated with the intermediate endpoints. Sub-
sequently, sets of proteins and intermediate end-
points were analyzed together by another statistical 
tool (Principal Components Analysis or PCA). 
PCA constructs factors that maximally explain the 
variance in the data, without relating the factors to 
another outcome variable (or a set of outcome 
variables). PCA analysis indicated that proteins 
involved in inflammation explained most of the 
variance, followed by proteins involved in 
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metabolism and proteins associated with total 
cholesterol. This study is one of the first in which 
the association of a large number of plasma 
proteins with CHD mortality and intermediate 
endpoints is investigated by applying multivariate 
statistics, providing insight in the relationships 
among proteins, intermediate endpoints and CHD 
mortality, and a set of proteins with prognostic 
value. 
 
Title: The HDL proteome: a marker--and perhaps 
mediator--of coronary artery disease. 
Author: Heinecke JW. 
Journal: J Lipid Res. 2009 Apr;50 Suppl:S167-71. 
Epub 2008 Dec 5. 
Comment: One important cardioprotective func-
tion of HDL is to remove cholesterol from lipid-
laden macrophages in the artery wall. HDL also 
exerts anti-inflammatory effects that might inhibit 
atherogenesis. However, HDL has been proposed 
to be dysfunctional in humans with established 
coronary artery disease (CAD), though the under-
lying mechanisms are unclear. Therefore, the 
author used mass spectrometry to investigate the 
roles of HDL proteins in inflammation and cardio-
vascular disease. Shotgun proteomic analysis iden-
tified multiple complement regulatory proteins, 
protease inhibitors, and acute-phase response 
proteins in HDL, strongly implicating the lipopro-
tein in inflammation and the innate immune 
system. Moreover, mass spectrometry and bio-
chemical analyses demonstrated that HDL3 from 
subjects with clinically significant CAD was selec-
tively enriched in apolipoprotein E, suggesting that 
it carries a distinctive protein cargo in humans with 
atherosclerosis. HDL from CAD subjects also 
contained markedly elevated levels of chloro-
tyrosine and nitrotyrosine, two characteristic pro-
ducts of myeloperoxidase, indicating that oxidative 
damage might generate dysfunctional HDL. 
Aggressive lipid therapy with a statin and niacin re-
modeled the HDL proteome to resemble that of 
apparently healthy subjects. Collectively, these 
observations indicate that quantifying the HDL 
proteome by mass spectrometry should help 
identify novel anti-inflammatory and cardiopro-
tective actions of HDL and provide insights into 
lipid therapy. 
Title: A “new” thematic series: mass spectrometry-
based proteomics of lipid biology. 
Author: Heinecke JW. 
Journal: J Lipid Res. 2009 May;50(5):777-80. 
Epub 2009 Mar 2. 
Comment: This editorial inaugurates JLR’s “new” 
thematic series that highlights the applications of 
mass spectrometry to the study of proteins 
important in lipid metabolism and biology. Prote-
omics, a global approach to understanding protein 
expression, regulation, and function, transcends 
analysis of individual proteins. The author first 
briefly reviews mass spectrometry, a major tool of 
proteomic research, then the 5 topics of the “new” 
thematic series: proteomic analysis of lipid-protein 
complexes (see below in May issue), eicosanoid 
class of molecules (see below in June issue), 
emerging field of lipoprotein proteomics, the role 
of lipid rafts, and proteomics of lipid droplets. 
 
Title: Thematic review series: Proteomics. Prote-
omic analysis of lipid-protein complexes. 
Author: Vaisar T. 
Journal: J Lipid Res. 2009 May;50(5):781-6. Epub 
2009 Feb 19. 
Comment: This is the first article in the JLR’s 
“new” thematic review series. There is intense in-
terest in comprehensive proteomic approaches for 
analyzing integral membrane proteins and lipopro-
teins. Lipid-associated proteins present a unique 
set of challenges to proteomic analysis. Key fea-
tures of any MS analysis center on enriching bio-
logical material for proteins of interest, efficiently 
digesting them, extracting the resulting peptides, 
and using fractionation methods to comprehen-
sively sample proteins or peptides by MS/MS. 
Integral membrane proteins have been extensively 
investigated by a number of well-validated proto-
cols. In contrast, analysis of lipoprotein particles 
has received limited attention, and optimal ap-
proaches for comprehensive proteomic analysis 
are still being developed. Although the lessons 
learned while analyzing integral membrane pro-
teins will undoubtedly benefit proteomic investi-
gations of lipoproteins, unique features, especially 
the dominance of a few proteins in each particle 
type, will require innovative methods for detecting 
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low-abundance proteins in these protein-lipid 
complexes. 
 
Title: Thematic review series: Proteomics. An 
integrated omics analysis of eicosanoid biology. 
Authors: Buczynski MW, Dumlao DS, Dennis EA. 
Journal: J Lipid Res. 2009 Jun;50(6):1015-38. 
Epub 2009 Feb 24. 
Comment: This is the second article in the JLR’s 
“new” thematic review series. Eicosanoids are sig-
naling molecules made by oxygenation of twenty-
carbon essential fatty acids (EFAs). They derive 
from either omega-3 (ω-3) or omega-6 (ω-6) EFAs. 
The ω-6 eicosanoids are generally pro-inflamma-
tory; ω-3s are much less so. There are four families 
of eicosanoids—prostaglandins, prostacyclins, 
thromboxanes and leukotrienes. For each, there 
are two or three separate series, derived either 
from an ω-3 or ω-6 EFA. These series’ different 
activities largely explain the health effects of ω-3 
and ω-6 fats. Eicosanoids have been implicated in 
a vast number of devastating inflammatory con-
ditions, including arthritis, atherosclerosis, pain, 
and cancer. Currently, over a hundred different 
eicosanoids have been identified, with many 
having potent bioactive signaling capacity. These 
lipid metabolites are synthesized de novo by at least 
50 unique enzymes, many of which have been 
cloned and characterized. Due to the extensive 
characterization of eicosanoid biosynthetic path-
ways, this field provides a unique framework for 
integrating genomics, proteomics, and metabol-
omics toward the investigation of disease pathol-
ogy. To facilitate a concerted systems biology 
approach, this review outlines the proteins impli-
cated in eicosanoid biosynthesis and signaling in 
human, mouse, and rat. Applications of the 
extensive genomic and lipidomic research to date 
illustrate the questions in eicosanoid signaling that 
could be uniquely addressed by a thorough analysis 
of the entire eicosanoid proteome. 
 
